Why Regeneron Could Be the Best Stock to Buy Tomorrow—Here's What You Need to Know

The Setup: A Biotech Giant Fighting Back

Regeneron Pharmaceuticals (NASDAQ: REGN) has taken its lumps over the past 18 months, but here’s the thing—the pressure is easing, and the company is setting itself up for a meaningful comeback. Two major catalysts suggest there’s real money to be made if you’re willing to look beneath the surface.

Eylea’s Evolution: Competition Doesn’t Mean Decline

Let’s start with the elephant in the room: Eylea, Regeneron’s blockbuster treatment for wet age-related macular degeneration, faced serious headwinds as new competitors entered the market. Sales took a hit, and investors panicked. Fair enough. But Regeneron didn’t sit idle.

The company rolled out a high-dose Eylea formulation that changes the game—literally. Instead of dosing every four to eight weeks, patients now get treatments spaced eight to 16 weeks apart after initial starter doses. That’s a massive quality-of-life improvement, and it matters more than you’d think in healthcare.

Recently, the FDA approved this high-dose version for macular edema following retinal vein occlusion (RVO), with an even more patient-friendly schedule: once every eight weeks after monthly startup doses. This wasn’t just another approval—Regeneron scored the first-ever FDA greenlight for RVO treatment with this dosing schedule. That positions high-dose Eylea as a serious competitive weapon against Vabysmo and helps offset biosimilar competition that’s been eating into margins.

The Pipeline: Where Real Growth Lives

Here’s where it gets interesting for the best stock to buy tomorrow candidates. Eylea stabilization is only part of the story. Regeneron’s pipeline is genuinely stacked with potential winners.

Cemdisiran showed impressive results in phase 3 trials for generalized myasthenia gravis, a chronic muscle-weakening disease. Regulatory filings are coming next year—this is a real near-term catalyst.

Then there’s the GLP-1 muscle preservation angle. Weight-loss drugs are everywhere now, but they have a problem: patients lose muscle mass along with fat. Regeneron’s trevogrumab is being developed specifically to solve this, and phase 2 data looked solid. If this works, it’s not just a treatment—it’s a franchise builder in a massive market.

Beyond that, Regeneron has a gene therapy candidate for hearing loss showing strong clinical trial performance. That’s early-stage, but gene therapy is where the real money flows once it works.

The Math: Why Now Matters

The stock is trading well below where it was mid-2024. The company has tackled its most obvious problem (Eylea competition intensifying), newer therapies are moving through the pipeline on schedule, and approvals should start driving top-line growth within the next few years.

Multiple expansion from here isn’t guaranteed, but the risk-reward setup is getting more attractive. For investors looking at the best stock to buy tomorrow in the biotech space, Regeneron’s combination of product stabilization and pipeline diversity is worth serious consideration.

The dip has created opportunity. Whether you pull the trigger depends on your risk tolerance, but the pieces are lining up nicely.